Doheny Asset Management CA Purchases Shares of 4,665 Teladoc Health, Inc. (NYSE:TDOC)

Doheny Asset Management CA purchased a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,665 shares of the health services provider’s stock, valued at approximately $46,000.

Several other institutional investors and hedge funds have also made changes to their positions in TDOC. Norges Bank purchased a new position in shares of Teladoc Health in the 4th quarter valued at $9,714,000. Parallel Advisors LLC boosted its stake in Teladoc Health by 14.6% in the fourth quarter. Parallel Advisors LLC now owns 4,038 shares of the health services provider’s stock valued at $87,000 after acquiring an additional 515 shares in the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Teladoc Health by 15.4% during the fourth quarter. Allianz Asset Management GmbH now owns 604,238 shares of the health services provider’s stock worth $13,021,000 after purchasing an additional 80,805 shares during the last quarter. Treasurer of the State of North Carolina increased its position in shares of Teladoc Health by 2.2% during the fourth quarter. Treasurer of the State of North Carolina now owns 73,127 shares of the health services provider’s stock worth $1,576,000 after purchasing an additional 1,570 shares in the last quarter. Finally, Pinebridge Investments L.P. increased its position in shares of Teladoc Health by 83.2% during the fourth quarter. Pinebridge Investments L.P. now owns 55,428 shares of the health services provider’s stock worth $1,194,000 after purchasing an additional 25,171 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Teladoc Health news, CMO Stephany Verstraete sold 15,000 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total value of $114,000.00. Following the completion of the transaction, the chief marketing officer now directly owns 45,158 shares of the company’s stock, valued at $343,200.80. The sale was disclosed in a filing with the SEC, which is available at this link. In other Teladoc Health news, CMO Stephany Verstraete sold 15,000 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.60, for a total transaction of $114,000.00. Following the sale, the chief marketing officer now directly owns 45,158 shares in the company, valued at $343,200.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Vidya Raman-Tangella sold 3,857 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total value of $31,395.98. Following the completion of the transaction, the insider now owns 33,667 shares of the company’s stock, valued at approximately $274,049.38. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,819 shares of company stock valued at $442,204. Corporate insiders own 0.95% of the company’s stock.

Analyst Ratings Changes

TDOC has been the subject of a number of research analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a research report on Thursday, August 1st. Oppenheimer lowered their target price on shares of Teladoc Health from $21.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Barclays reduced their price target on shares of Teladoc Health from $20.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. JPMorgan Chase & Co. decreased their price target on shares of Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, August 26th. Finally, Truist Financial dropped their price objective on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating on the stock in a research note on Friday, August 2nd. Fifteen investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $12.31.

Teladoc Health Stock Up 0.6 %

Teladoc Health stock opened at $8.46 on Friday. The stock’s 50 day moving average price is $7.93 and its 200 day moving average price is $10.65. Teladoc Health, Inc. has a 1-year low of $6.76 and a 1-year high of $22.54. The company has a market cap of $1.43 billion, a PE ratio of -6.00 and a beta of 0.90. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.62.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, July 31st. The health services provider reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.08. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. The company had revenue of $642.44 million for the quarter, compared to analyst estimates of $649.34 million. On average, sell-side analysts predict that Teladoc Health, Inc. will post -1.18 EPS for the current fiscal year.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.